IMTX
NASDAQ HealthcareImmatics N.V. - Ordinary Shares
Biotechnology
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
�� 市场数据
| 价格 | $11.17 |
|---|---|
| 成交量 | 352,896 |
| 市值 | 1.50B |
| 贝塔系数 | 1.340 |
| RSI（14日） | 81.5 超买 |
| 200日均线 | $8.80 |
| 50日均线 | $10.03 |
| 52周最高 | $12.41 |
| 52周最低 | $3.94 |
| Forward P/E | -6.30 |
| Price / Book | 2.62 |
🎯 投资策略评分
IMTX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (76/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (14/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 IMTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 IMTX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.